Astaxanthin (an Nrf2 activator) and meclizine (an mTORC1 inhibitor) extended the median lifespan of male mice by 12% and 8% respectively within the ITP program.

noli's read

Brad Stanfield faithfully reports the recent results of the National Institute on Aging's Interventions Testing Program (ITP), which is a solid benchmark in aging research using murine models. These studies are randomized controlled trials (RCTs) in mice, which constitutes robust preclinical evidence for identifying promising candidates. It is crucial to note that these results concern only mice, and there is an immense biological leap between these models and humans. Direct extrapolation to human longevity is therefore a common exaggeration: we do not know if these substances would produce similar effects, nor what the appropriate dosage or long-term safety profile would be in humans. Longevity science is still in an exploratory phase regarding these specific molecules, and no clinical evidence validates these benefits in healthy individuals. The creator remains factual regarding the animal data, but the context suggests immediate applicability that remains to be demonstrated.

the sources

No named source held this one up — that absence is part of the verdict.